Aldeyra Therapeutics (ALDX) Current Assets (2013 - 2026)

Aldeyra Therapeutics' Current Assets history runs 14 years deep, the most recent figure standing at $66.3 million for Q1 2026.

• Quarterly Current Assets fell 28.53% year-over-year to $66.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $66.3 million (down 28.53% YoY) and the FY2025 annual result came in at $71.8 million, down 31.03% from the prior year.
• Current Assets was $66.3 million for Q1 2026 at Aldeyra Therapeutics, down from $71.8 million in the prior quarter.
• Across five years, Current Assets topped out at $222.4 million in Q1 2022 and bottomed at $66.3 million in Q1 2026.
• A 5-year average of $134.8 million and a median of $140.8 million in 2024 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2022 — Current Assets surged 51.19% — and 2025, when it sank 34.16%.
• Aldeyra Therapeutics' Current Assets stood at $181.0 million in 2022, then dropped by 18.35% to $147.8 million in 2023, then retreated by 29.59% to $104.1 million in 2024, then plunged by 31.03% to $71.8 million in 2025, then decreased by 7.68% to $66.3 million in 2026.
• Business Quant data shows ALDX's Current Assets at $66.3 million in Q1 2026, $71.8 million in Q4 2025, and $77.5 million in Q3 2025.